VeriStar Capital Management LP Takes $4.99 Million Position in IQVIA Holdings Inc. $IQV

Key Points

• VeriStar Capital Management LP has acquired a new position in IQVIA Holdings, purchasing 28,284 shares valued at approximately $4.99 million, which now represents about 9.1% of their total holdings.
• IQVIA reported strong earnings with $2.81 EPS for the last quarter, surpassing analyst expectations and indicating a 5.3% year-over-year revenue increase.
• Analysts maintain a consensus rating of "Moderate Buy" with a target price of $228.62, despite JPMorgan lowering its target to $177.00.

VeriStar Capital Management LP acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 28,284 shares of the medical research company's stock, valued at approximately $4,986,000. IQVIA makes up about 9.1% of VeriStar Capital Management LP's portfolio, making the stock its 5th largest position.

Several other institutional investors and hedge funds have also made changes to their positions in IQV. American National Bank & Trust bought a new position in shares of IQVIA in the first quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares in the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares in the last quarter. AllSquare Wealth Management LLC bought a new stake in IQVIA during the first quarter worth approximately $33,000. Finally, ST Germain D J Co. Inc. boosted its holdings in IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Trading Up 2.0%

Shares of NYSE:IQV traded up $3.67 during mid-day trading on Friday, hitting $187.75. The stock had a trading volume of 1,263,215 shares, compared to its average volume of 1,128,696. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $31.92 billion, a PE ratio of 27.17, a P/E/G ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $249.43. The company's 50 day moving average is $179.88 and its 200-day moving average is $167.41.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the prior year, the firm earned $2.64 EPS. The firm's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IQV. Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. William Blair restated an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays raised their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Mizuho raised their target price on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, Cowen restated a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $229.86.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.